Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQA3605 in chronic HBV infection with low-level viremia
NCT06644417Phase 2Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Nov 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of TQA3605 in Chronic Hepatitis B (CHB), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Nov 2024; status: completed.
02
Drugs
TQA3605
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06644417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06644417.